Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors

Journal of Clinical Oncology

Volumn 28, Issue 23, 2010, Pages 3746-3753

  Kaira, Kyoichi ^a   Endo, Masahiro ^a   Abe, Masato ^a   Nakagawa, Kazuo ^a   Ohde, Yasuhisa ^a   Okumura, Takehiro ^a   Takahashi, Toshiaki ^a   Murakami, Haruyasu ^a   Tsuya, Asuka ^a   Nakamura, Yukiko ^a   Naito, Tateaki ^a   Hayashi, Isamu ^a   Serizawa, Masakuni ^a   Koh, Yasuhiro ^a   Hanaoka, Hirofumi ^a   Tominaga, Hideyuki ^a   Oriuchi, Noboru ^a   Kondo, Haruhiko ^a   Nakajima, Takashi ^a   Yamamoto, Nobuyuki ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BAG 1 PROTEIN; CD31 ANTIGEN; CD34 ANTIBODY; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN P53; VASCULOTROPIN; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG UPTAKE; EPITHELIUM TUMOR; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MICROVASCULATURE; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THYMOMA; UPREGULATION; CANCER STAGING; CARCINOMA; METABOLISM; MIDDLE AGED; PATHOLOGY; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THYMUS NEOPLASMS;

EID: 77957259710     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.4662     Document Type: Article

References (48)

1. Engels EA, Pfeiffer RW: Malignant thymoma in the United States: Demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer 105:546-551, 2003 (Pubitemid 36578561)
2. Rosai J, Sobin LH: Histological typing of tumours of the thymus, in International Histological Classification of Tumours, ed 2. New York, NY, Springer, 1999, pp 1-59
3. Brambilla E, Travis WD, Colby TV, et al: The new World Health Organization classification of lung tumours. Eur J Respir 18:1059-1068, 2001
4. Pieterman RM, van Putten JW, Meuzelaar JJ, et al: Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 343:254-261, 2000 (Pubitemid 30490393)
5. Lardinois D, Weder W, Hany TF, et al: Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348:2500-2507, 2003 (Pubitemid 36706537)
6. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al: Lymph node staging in non-small-cell lung cancer with FDG-PET scan: A prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 16:2142-2149, 1998 (Pubitemid 28265051)
7. Brock CS, Meikle SR, Price P: Dose fluorine-18 fluorodeoxyglucose metabolic imaging of tumor benefit oncology? Eur J Nucl Med 24:691-705, 1997
8. Hoffman JM, Waskin HA, Schifter T, et al: FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med 34:567-575, 1993 (Pubitemid 23115656)
9. 18F] FDG uptake in non-small cell lung cancer. Eur J Nucl Med 27:1778-1785, 2000
10. 8F-FDG PET results in lung cancer staging. J Nucl Med 45:999-1003, 2004
11. Liu RS, Yoho SH, Huang MH, et al: Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of thymoma: A preliminary report. Eur J Nucl Med 22:1402-1407, 1995
12. Kubota K, Yamada S, Kondo T, et al: PET imaging of primary mediastinal tumours. Br J Cancer 73:882-886, 1996 (Pubitemid 26110157)
13. 11C-methionine PET and FDG PET. J Nucl Med 40:1595-1601, 1999
14. 18F-FDG PET/CT of thymic epithelial tumors: Usefulness of distinguishing and staging tumor subgroups. J Nucl Med 47:1628-1634, 2006
15. El-Bawab H, Al-Sugair AA, Rafay M, et al: Role of fluorine-18 fluorodeoxyglucose positron emission tomography in thymic pathology. Eur J Cardiothorac Surg 31:731-736, 2007 (Pubitemid 46400514)
16. 18FDG-PET for differentiating the grade of malignancy in thymic epithelial tumors. Lung Cancer 61:350-355, 2008
17. 18FDG PET-CT. Ann Nucl Med 23:569-577, 2009
18. Kojika M, Ishii G, Yoshida J, et al: Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: Diagnostic utility of hypoxic marker, GLUT1, in thymic epithelial neoplasms. Mod Pathol 22:1341-1350, 2009
19. Vleugel MM, Greijer AE, Shvarts, et al: Differential prognostic impact of hypoxia induced and diffuse HIF-1 alpha expression in invasive breast cancer. J Clin Pathol 58:172-177, 2005 (Pubitemid 40193803)
20. Elson DA, Ryan HE, Snow JW, et al: Coordinate up-regulation of hypoxia inducible factor (HIF)-1a and HIF-1 target genes during multi-stage epidermal carcinogenesis and wound healing 1. Cancer Res 60:6189-6195, 2000
21. Burgman P, Odonoghue JA, Humm JL, et al: Hypoxia-induced increase in FDG uptake in MCF7 cells. J Nucl Med 42:170-175, 2001 (Pubitemid 32104796)
22. Thomas GV, Tran C, Mellinghoff IK, et al: Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12:122-127, 2006 (Pubitemid 43050086)
23. Guo J, Higashi K, Ueda Y, et al: Microvessel density: Correlation with 18F-FDG uptake and prognosis impact in lung adenocarcinomas. J Nucl Med 47:419-425, 2006 (Pubitemid 46768483)
24. 18F-FDG uptake in non-small cell lung cancer. Cancer Sci 100:753-758, 2009
25. Ryan HE, Polling M, McNulty W, et al: Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res 60:4010-4015, 2000 (Pubitemid 30636574)
26. Masaoka A, Monden Y, Nakahara K, et al: Follow-up study of thymomas with special reference to their clinical stages. Cancer 48:2485-2492, 1981 (Pubitemid 12228012)
27. 18F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1α and GLUT-1 in non-small cell lung cancer. Eur J Cancer 43:1392-1398, 2007
28. Kaira K, Oriuchi N, Shimizu K, et al: Evaluation of thoracic tumors with (18)F-FMT and (18)F-FDG PET-CT: A clinicopathological study. Int J Cancer 124:1152-1160, 2009
29. Hiroshima K, Iyoda A, Toyozaki T, et al: Proliferative activity and apoptosis in thymic epithelial neoplasms. Mod Pathol 15:1326-1332, 2002 (Pubitemid 35463001)
30. Weidner N, Semple JP, Welch WR, et al: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991
31. Mineo TC, Ambrogi V, Baldi A, et al: Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumor vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol 57:591-597, 2004 (Pubitemid 38725758)
32. 2-adrenoceptors on glycogenolysis. Neuropsychopharmacology 33:2384-2397, 2008
33. Moon SY, Chang HW, Roh JL, et al: Using YC-1 to overcome the radioresistance of hypoxic cancer cells. Oral Oncol 45:915-919, 2009
34. Hayashi M, Sakata M, Takeda T, et al: Induction of glucose transporter 1 expression through hypoxia-inducible factor 1α under hypoxic conditions in trophoblast-derived cells. J Endocrinol 183:145-154, 2004 (Pubitemid 40124651)
35. Vissers MC, Gunningham SP, Morrison MJ, et al: Modulation of hypoxia-inducible factor-1 alpha in cultured primary cells by intracellular ascorbate. Free Radic Biol Med 42:765-772, 2007 (Pubitemid 46274164)
36. Isselbacher KJ: Sugar and amino acid transport by cells in culture: Differences between normal and malignant cells. N Engl J Med 286:929-933, 1972
37. Mueckler M: Facilitative glucose transporters. Eur J Biochem 219:713-725, 1994
38. Yamamoto T, seino Y, Fukumoto H, et al: Over-expression of facilitative glucose transporter genes in human cancers. Biochem Biophys Res Commun 170:223-230, 1990 (Pubitemid 20249408)
39. Younes M, Brown RW, Stephenson M, et al: Over expression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 80:1046-1051, 1997 (Pubitemid 27427603)
40. Kaira K, Oriuchi N, Imai H, et al: L-type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas. J Surg Oncol 99:433-438, 2009
41. Tomita M, Matsuzaki Y, Edagawa M, et al: Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors. J Thorac Cardiovasc Surg 124:493-498, 2002
42. Mineo TC, Ambrogi V, Baldi A, et al: Recurrent intrathoracic thymomas: Potential prognostic importance of cell-cycle protein expression. J Thorac Cardiovasc Surg 138:40-45, 2009
43. Khoury T, Arshad A, Bogner P, et al: Apoptosis-related (surviving, bcl-2), tumor suppressor gene (p53), proliferation (Ki-67), and non-receptor tyrosine kinase (src) markers expression and correlation with clinicopathologic variables in 60 thymic neoplasms. Chest 136:220-228, 2009
44. Taylor MD, Smith PW, Brix WK, et al: Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer. J Thorac Cardiovasc Surg 137:43-48, 2009
45. Riedl CC, Akhurst T, Larson S, et al: 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med 48:771-775, 2007 (Pubitemid 47604978)
46. Chen G, Marx A, Wen-Hu C, et al: New WHO histologic classification predicts prognosis of thymic epithelial tumors. Cancer 95:420-429, 2002
47. Kim DJ, Yang WL, Choi SS, et al: Prognostic and clinical relevance of the World Health Organization Schema for the classification of thymic epithelial tumors. Chest 127:755-761, 2005
48. de Geus-Oei LF, van der Heijden HF, Corstens FH, et al: Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: A systemic review. Cancer 110:1654-1664, 2007 (Pubitemid 47557290)